Purpose: To evaluate feasibility and image quality of time-resolved contrast-enhanced magnetic resonance angiography (CEMRA) of the left atrium-pulmonary veins (LA-PV) complex with half dose of intravenous gadolinium-based contrast agent (GBCA) in patients candidate to percutaneous radiofrequency ablation of atrial fibrillation. Methods and materials: Fifty-seven patients underwent CEMRA of the LA-PV complex on a 1.5 T MRI scanner. On 24/57 patients, a conventional fast-spoiled gradient-echo (FSPGR) CEMRA acquisition was run using 0.2 mL/kg of 0.5 M GBCA at 2 mL/s flow rate (protocol A), while in 33/57 patients a time-resolved multiphase CEMRA sequence (Time-Resolved Imaging of Contrast KineticS, TRICKS) was performed after intravenous injection of 0.1 mL/kg of the same GBCA at 3 mL/s flow rate (protocol B). Contrast enhancement was measured in the LA (LAe) and in the PA (PAe), and the LAe/PAe ratio was calculated. Diagnostic quality of Maximum Intensity Projection (MIP), Volume Rendering (VR), and Virtual Endoscopy (VE) reconstructions was also assessed visually using a semiquantitative score. Results: LAe was comparable with both protocols, while PAe was lower with protocol B than with protocol A (p = 0.0217). Moreover, the LAe/PAe ratio was significantly higher with protocol B than with protocol A (p = 0.0044). Finally, image quality of MIP, VR, and VE reconstructions was significantly better with protocol B than with protocol A (p = 0.0005, p = 0.0001, and p = 0.005, respectively). Conclusions: CEMRA of the LA-PV complex is feasible with TRICKS and half-dose GBCA and yields better separation between the LA-PV complex and the PA, as well as better image quality of MIP, VR, and VE reconstructions than a conventional FSPGR sequence performed with full GBCA dose.
|Autori:||Faggioni L; Zampa V; Ortori S; Picano E; De Lucia R; Soldati E; Bongiorni MG; Neri E; Bartolozzi C.|
|Titolo:||Time-resolved contrast-enhanced magnetic resonance angiography (CEMRA) of the left atrium-pulmonary veins complex with half dose of intravenous gadolinium-based contrast agent. Technical feasibility and comparison with a conventional CEMRA, full contrast dose protocol.|
|Anno del prodotto:||2012|
|Digital Object Identifier (DOI):||10.1016/j.ejrad.2010.12.096|
|Appare nelle tipologie:||1.1 Articolo in rivista|